{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:04:12Z","timestamp":1776089052754,"version":"3.50.1"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["INT20\/00079"],"award-info":[{"award-number":["INT20\/00079"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["INT23\/00017"],"award-info":[{"award-number":["INT23\/00017"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer's Disease Reports"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Novel therapies for Alzheimer's disease are expected to increase the demand for biomarkers. PET will likely play a central role in patient selection and treatment monitoring, requiring adequate infrastructure and trained professionals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the current status of Nuclear Medicine departments in Spain regarding organization, expertise, and available infrastructure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a nationwide survey among Nuclear Medicine departments in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Respondents averaged 19.8 years of professional experience; 62.0% had specific neuroimaging training and 76.0% reported high confidence in amyloid PET interpretation. Hospitals were mainly public (70.6%) and widely distributed geographically, and 73.0% reported having cognitive impairment units. Following the INVEAT plan, Spain currently has 147 PET scanners, although capacity varies: most centers operate one scanner and five reported having none. Amyloid PET is available in 77.0% of departments, with annual volumes ranging from fewer than 10 to more than 100 studies; 15.0% cannot perform amyloid PET due to regional limitations. Quantification tools are available in 41.3% of centers, although only 15.5% include quantitative metrics in reports, while 66.7% support the use of centiloid standardization. Nearly all respondents anticipate increased indications for amyloid PET (screening 83.7%; monitoring 68.5%) and support multidisciplinary collaboration (89.1% favor Neuroimaging Committees). About half report workforce needs, mainly nuclear medicine physicians (46.2%). Research activity in Alzheimer's disease is expected to increase (95.6%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most departments recognize the key role of amyloid PET for anti-amyloid therapy implementation and anticipate increased demand, highlighting the need to expand availability, implement quantification tools, and strengthen multidisciplinary collaboration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/25424823261437129","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:28:37Z","timestamp":1776086917000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Current use and perspectives of PET imaging in Alzheimer's disease: A Spanish national survey"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-3200","authenticated-orcid":false,"given":"Mar\u00eda Nieves","family":"Cabrera-Mart\u00edn","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Hospital Cl\u00ednico San Carlos, San Carlos Health Research Institute (IdISSC), Universidad Complutense de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Aguiar-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Santiago de Compostela University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valle","family":"Camacho-Mart\u00ed","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5693-9311","authenticated-orcid":false,"given":"Edgar F","family":"Guill\u00e9n-Valderrama","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Clinica Universidad de Navarra, CCUN Applied Medical Research, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio Francisco","family":"Jim\u00e9nez-Bonilla","sequence":"additional","affiliation":[{"name":"University Hospital Marqu\u00e9s de Valdecilla, Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla (IDIVAL), Universidad de Cantabria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-8250","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"Lojo-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Alfonso","family":"L\u00f3pez-Mora","sequence":"additional","affiliation":[{"name":"Consorci Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5520-2708","authenticated-orcid":false,"given":"Jordi A","family":"Mat\u00edas-Guiu","sequence":"additional","affiliation":[{"name":"Department of Neurology. Hospital Cl\u00ednico San Carlos, San Carlos Health Research Institute (IdISSC), Universidad Complutense de Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Paredes-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Perissinotti","sequence":"additional","affiliation":[{"name":"Biomaterials and Nanomedicine (CIBER-BBN), ICSIII"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-5510","authenticated-orcid":false,"given":"Javier","family":"Arbizu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Clinica Universidad de Navarra, CCUN Applied Medical Research, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"31","article-title":"NIA-AA Research framework: toward a biological definition of Alzheimer's disease","volume":"19","author":"Jack CR","year":"2023","unstructured":"Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2023; 19: 31\u201345.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_3_6_2","article-title":"Alzheimer\u2019s disease drug development pipeline: 2024","volume":"10","author":"Cummings J","year":"2024","unstructured":"Cummings J, Zhou Y, Lee G, et al. Alzheimer\u2019s disease drug development pipeline: 2024. Alzheimers Dement (N Y) 2024; 10: e12465.","journal-title":"Alzheimers Dement (N Y)"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4032-1"},{"key":"e_1_3_3_8_2","first-page":"931","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B","volume":"57","author":"Klunk WE","year":"2015","unstructured":"Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2015; 57: 931\u2013939.","journal-title":"Ann Neurol"},{"key":"e_1_3_3_9_2","article-title":"Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele R","year":"2025","unstructured":"Ossenkoppele R, van der Kant R, Hansson O, et al. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. Alzheimers Dement 2025; 21: e14338.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004058"},{"key":"e_1_3_3_11_2","article-title":"Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s association and society for nuclear medicine and molecular imaging workgroup","volume":"21","author":"Rabinovici GD","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s association and society for nuclear medicine and molecular imaging workgroup. J Nucl Med 2025; 21: e14338.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0528"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2023.166"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/13872877241284312"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07066-9"},{"key":"e_1_3_3_16_2","unstructured":"Plan INVEAT. Inversi\u00f3n en equipos de alta tecnolog\u00eda sanitaria en el Sistema Nacional de Salud. https:\/\/www.sanidad.gob.es\/profesionales\/prestacionesSanitarias\/PlanINVEAT\/pdf\/Plan_INVEAT.pdf"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01883-X"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.20240203"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-2566-1487"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.03.004"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.4596"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11703"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07323-x"},{"key":"e_1_3_3_27_2","first-page":"239","article-title":"Validation technique and improvements introduced in a new dedicated brain positron emission tomograph (CareMiBrain)","volume":"40","author":"Cabrera-Mart\u00edn MN","year":"2021","unstructured":"Cabrera-Mart\u00edn MN, Gonz\u00e1lez-Pav\u00f3n G, Sanch\u00eds Hern\u00e1ndez M, et al. Validation technique and improvements introduced in a new dedicated brain positron emission tomograph (CareMiBrain). Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021; 40: 239\u2013248.","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-220841"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-220046"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14528"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-200890"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-190220"}],"container-title":["Journal of Alzheimer's Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823261437129","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25424823261437129","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823261437129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:28:45Z","timestamp":1776086925000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25424823261437129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"alternative-id":["10.1177\/25424823261437129"],"URL":"https:\/\/doi.org\/10.1177\/25424823261437129","relation":{},"ISSN":["2542-4823","2542-4823"],"issn-type":[{"value":"2542-4823","type":"print"},{"value":"2542-4823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"25424823261437129"}}